Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

NCT05686070 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05686070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
January 26, 2023
Completion date
October 23, 2025
Enrollment
12,327 (actual)
Sites
741

Conditions

As the registry lists them; a condition with its own page is linked.

acute non-cardioembolic ischemic stroke, high-risk transient ischemic attack, prevention of ischemic stroke